Study guide

Potassium and sodium emergencies

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Potassium and sodium emergencies

Key Takeaways Explain This Topic AI

Hyperkalaemia with ECG changes requires urgent membrane stabilisation and potassium-lowering treatment.

Calcium gluconate and calcium chloride are not equivalent volume-for-volume.

High-risk hyponatraemia patients should not exceed an 8 mmol/L sodium rise in any 24 hours.

Last updated: October 2026

Hyperkalaemia: Emergency Management

Serum potassium > 5.5 mmol/L > 5.5\text{ mmol/L} > 5.5 mmol/L constitutes hyperkalaemia, with levels > 6.5 mmol/L > 6.5\text{ mmol/L} > 6.5 mmol/L or any potassium elevation associated with ECG changes constituting a medical emergency.

  • ECG Evolution in Hyperkalaemia
  • Tall, peaked, symmetrical T waves with a narrow base (earliest finding)
  • Prolongation of the PR interval and flattening or loss of P waves
  • Widening of the QRS complex
  • Merging of the wide QRS with the T wave forming a sine wave appearance
  • Ventricular fibrillation, idioventricular rhythm, or asystole
  • Stepwise Management Algorithm

Step 1: Cardiac Membrane Stabilization (Immediate):

Membrane protection: Give IV calcium for hyperkalaemic ECG toxicity under the local monitored protocol and repeat if needed. Calcium gluconate and calcium chloride have different elemental calcium concentrations; equal 10-mL volumes are not equivalent. Calcium stabilises the myocardium but does not remove potassium.

Mechanism: Antagonizes potassium-induced membrane excitability, normalizing threshold potential without lowering serum potassium levels.

Onset & Duration: Onset in 1 − 3 minutes 1 - 3\text{ minutes} 1 − 3 minutes ; duration of effect 30 − 60 minutes 30 - 60\text{ minutes} 30 − 60 minutes . Repeat dose after 5-10 minutes if ECG changes persist.

Step 2: Intracellular Potassium Shifting (Within 15-30 minutes):

Intravenous Insulin with Glucose: Short-acting insulin ( Actrapid 10 units 10\text{ units} 10 units ) added to 50 mL 50\text{ mL} 50 mL of 50 % 50\% 50% dextrose (or 100 mL 100\text{ mL} 100 mL of 20 % 20\% 20% dextrose) infused over 15 to 30 minutes. Stimulates the Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase pump, lowering serum potassium by 0.5 − 1.2 mmol/L 0.5 - 1.2\text{ mmol/L} 0.5 − 1.2 mmol/L within 30-60 minutes.

Nebulised Salbutamol: 10 − 20 mg 10 - 20\text{ mg} 10 − 20 mg via nebuliser (high dose, four times the asthma dose). β 2 \beta_2 β 2 ​ -adrenoceptor stimulation activates Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase.

Sodium Bicarbonate 8.4 % 8.4\% 8.4% : 50 − 100 mL 50 - 100\text{ mL} 50 − 100 mL IV over 10-20 minutes, indicated only if concurrent severe metabolic acidosis ( p H < 7.15 pH < 7.15 p H < 7.15 ) is present.

Step 3: Total-Body Potassium Elimination:

Loop Diuretics: Intravenous frusemide ( 40 − 80 mg 40 - 80\text{ mg} 40 − 80 mg ) in volume-replete patients with functioning kidneys.

Potassium Binders: Sodium zirconium cyclosilicate (SXC, Lokelma) or patiromer exchange potassium in the gastrointestinal tract.

Step 4: Emergency Haemodialysis (The AEIOU Criteria):

A cidosis: Severe refractory metabolic acidosis ( p H < 7.15 pH < 7.15 p H < 7.15 ).

E lectrolytes: Persistent, refractory hyperkalaemia ( > 6.5 mmol/L > 6.5\text{ mmol/L} > 6.5 mmol/L ) or recurrent malignant arrhythmias.

I ngestions: Toxic dialysable drugs (lithium, toxic alcohols, salicylates, metformin).

O verload: Refractory pulmonary oedema unresponsive to high-dose loop diuretics.

U raemia: Uraemic pericarditis, uraemic encephalopathy, asterixis, or uraemic bleeding diathesis.

Hyponatraemia: Diagnostic Classification & Correction Limits

Hyponatraemia (serum sodium < 135 mmol/L < 135\text{ mmol/L} < 135 mmol/L ) is the most common electrolyte disorder in hospitalized patients.

  • Diagnostic Algorithm for Hypotonic Hyponatraemia
  • Syndrome of Inappropriate ADH Secretion (SIADH)

Essential Diagnostic Criteria:

Hypotonic hyponatraemia (plasma osmolality < 275 mOsm/kg < 275\text{ mOsm/kg} < 275 mOsm/kg )

Inappropriately concentrated urine (urine osmolality > 100 mOsm/kg > 100\text{ mOsm/kg} > 100 mOsm/kg , typically > 300 mOsm/kg > 300\text{ mOsm/kg} > 300 mOsm/kg )

Elevated urine sodium (urine Na > 30 mmol/L \text{Na} > 30\text{ mmol/L} Na > 30 mmol/L despite normal dietary intake)

Euvolaemic state on physical examination (no peripheral oedema, normal jugular venous pressure, normal skin turgor)

Normal adrenal, thyroid, and renal function, without concurrent diuretic therapy

Causes: Malignancy (small cell lung carcinoma in > 70 % > 70\% > 70% of paraneoplastic cases), central nervous system disorders (stroke, trauma, meningitis), pulmonary infections (pneumonia, tuberculosis), and drugs (SSRIs, carbamazepine, antipsychotics, PPIs, cyclophosphamide).

SIADH: Confirm hypotonic hyponatraemia and exclude adrenal deficiency, thyroid disease and relevant drugs. Fluid restriction is usual initial treatment when appropriate, tailored to intake/output and feasibility; oral urea or other specialist treatment may be needed. Tolvaptan is not a generic routine second-line choice and can overcorrect sodium.

Acute Hyponatraemia with Severe Neurological Symptoms

Patients presenting with severe neurovascular compromise (generalized tonic-clonic seizures, coma, respiratory depression, or signs of brainstem herniation) require emergent hypertonic saline.

Treatment: Infuse hypertonic 3 % 3\% 3% sodium chloride as a 100 − 150 mL 100 - 150\text{ mL} 100 − 150 mL IV bolus over 10 to 20 minutes . Repeat up to twice if severe symptoms persist, aiming for an immediate safe rise of 4 − 6 mmol/L 4 - 6\text{ mmol/L} 4 − 6 mmol/L to abort cerebral oedema.

The Golden Rule of Chronic Hyponatraemia: Safe Correction Limits

In chronic hyponatraemia ( > 48 hours > 48\text{ hours} > 48 hours ), brain cells adapt to hypotonicity by extruding intracellular osmolytes (myo-inositol, glutamate) to prevent cerebral swelling.

Rapid Correction Danger: Overly rapid sodium correction draws water out of brain cells, causing dehydration, blood-brain barrier disruption, and oligodendrocyte apoptosis leading to Osmotic Demyelination Syndrome (ODS) (formerly central pontine myelinolysis). Manifestations appear 2-6 days later: dysarthria, dysphagia, flaccid quadriparesis transitioning to spasticity, 'locked-in' syndrome, and permanent vegetative state.

Maximum Safe Correction Limit: ≤ 8 mmol/L \le 8\text{ mmol/L} ≤ 8 mmol/L in any 24-hour period (and ≤ 4 − 6 mmol/L \le 4-6\text{ mmol/L} ≤ 4 − 6 mmol/L in patients with high risk: chronic alcoholism, malnutrition, advanced cirrhosis, hypokalaemia).

Emergency Re-lowering: If accidental overcorrection occurs, immediately cease hypertonic/isotonic fluids, administer intravenous 5 % 5\% 5% dextrose, and give desmopressin (DDAVP) to halt urinary free water loss.

Monitoring potassium and sodium treatment

After insulin/dextrose for hyperkalaemia, monitor glucose for several hours, particularly in renal failure; delayed hypoglycaemia can occur. Repeat potassium and ECG because shifting treatment is temporary and rebound is possible. Stop potassium sources and arrange definitive removal, including dialysis when indicated.

For severe symptomatic hyponatraemia, use monitored hypertonic saline under the emergency pathway, often initially targeting a 4–6 mmol/L rise sufficient to control symptoms. High-risk patients should not exceed 8 mmol/L in any 24 hours. Check sodium frequently and obtain urgent advice for overcorrection, potentially requiring desmopressin and controlled free-water replacement. A ceiling is not the intended daily target.

Primary references (checked 7 October 2026): KDIGO CKD guidance .